TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37286319

Group type: EXPERIMENTAL
Intervention: Visual and auditory contact via a head-mounted display (HMD) showing a live video of the newborn, used by the mother during surgery.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment-as-usual (standard care) for mothers after CS.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Visual and auditory contact via HMD.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment-as-usual (standard care).
Number of subjects: 70
Study: 37286324

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX treatment with circadian-based telemonitoring-telecare platform
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX treatment
Number of subjects: 67
Study: 37286457

Group type: EXPERIMENTAL
Intervention: Radioligand treatment
Number of subjects: 0
Study: 37286557

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg every 3 weeks in cohort A (HER2-positive, IHC 3+ or IHC 2+/ISH+).
Number of subjects: 86

Group type: COMPARATOR
Intervention: Trastuzumab deruxtecan (T-DXd) in cohorts B and C (IHC 2+/ISH- and IHC 1+ respectively).
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in cohort A.
Number of subjects: 86
Study: 37286774

Group type: EXPERIMENTAL
Intervention: Medical student-guided smoking cessation program
Number of subjects: 688

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Medical student knowledge assessment
Number of subjects: 688
Study: 37286846

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32-34 °C for 24 h) plus standard care
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 270
Study: 37286927

Group type: EXPERIMENTAL
Intervention: Daridorexant
Number of subjects: 930

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 930
Study: 37287026

Group type: EXPERIMENTAL
Intervention: PSH Overdose Prevention (POP) Toolkit training, time-limited practice facilitation, and learning collaboratives delivered to staff and tenant implementation champions over a 6-month period.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PSH staff and tenant survey questionnaires and analysis of tenant Medicaid data.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with key stakeholders.
Number of subjects: 20
Study: 37287037

Group type: EXPERIMENTAL
Intervention: TLR4 and related genes (including SNP rs4986790 and rs5030719)
Number of subjects: 349
Study: 37287080

Group type: EXPERIMENTAL
Intervention: Current glucocorticoid (GC) treatment
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Cumulative GC dose and duration of use
Number of subjects: 483

Group type: COMPARATOR
Intervention: Not applicable (control group: patients not currently taking GCs)
Number of subjects: 483
Study: 37287104

Group type: EXPERIMENTAL
Intervention: Former WHO definition (PTA > 25 dB)
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: New WHO definition (PTA ≥ 20 dB)
Number of subjects: 1634
Study: 37287317

Group type: EXPERIMENTAL
Intervention: DDI (Decision to Delivery Interval) of more than 20 minutes
Number of subjects: 228

Group type: COMPARATOR
Intervention: DDI of 20 minutes or less
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DDI longer than 20 minutes
Number of subjects: 228
Study: 37287321

Group type: EXPERIMENTAL
Intervention: Active tDCS over the left inferior frontal gyrus (IFG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active tDCS over the left IFG
Number of subjects: 0
Study: 37287520

Group type: EXPERIMENTAL
Intervention: Modified Diabetes Prevention Program (DPP)
Number of subjects: 14
Study: 37287870

Group type: EXPERIMENTAL
Intervention: nal-IRI/5-FU/folinic acid
Number of subjects: 58

Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 58
Study: 37287922

Group type: EXPERIMENTAL
Intervention: hsa-miR-5096
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: hsa-let-7i-3p
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: hsa-miR-4311
Number of subjects: 24
Study: 37287970

Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone intravenously for 3 consecutive days followed by tocilizumab (TCZ) monotherapy
Number of subjects: 16
Study: 37288292

Group type: EXPERIMENTAL
Intervention: Bilateral neck exploration, left thyroid lobectomy, and transcervical thymectomy.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Repeat preoperative imaging identified a 7-mm × 5-mm adenoma on 4DCT.
Number of subjects: 1
Study: 37288326

Group type: EXPERIMENTAL
Intervention: 1-hour infusion group
Number of subjects: 96

Group type: COMPARATOR
Intervention: 2-hour infusion group
Number of subjects: 96
Study: 37288553

Group type: EXPERIMENTAL
Intervention: Catheter or surgical ablation of long-standing persistent atrial fibrillation
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: LA contractile strain at 3 months post-ablation
Number of subjects: 83
Study: 37288562

Group type: EXPERIMENTAL
Intervention: metagenomic next-generation sequencing (mNGS)
Number of subjects: 0
Study: 37288570

Group type: EXPERIMENTAL
Intervention: 7 SPC class combinations
Number of subjects: 3833

Group type: EXPERIMENTAL
Intervention: All medication class regimens
Number of subjects: 3833

Group type: EXPERIMENTAL
Intervention: 4 or more medication classes
Number of subjects: 3833
Study: 37288582

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy (NAICT) with toripalimab (PD-1 inhibitor) and albumin paclitaxel/cisplatin (TTP)
Number of subjects: 20
Study: 37288701

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 6104
Study: 37288954

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus 2 NRTIs
Number of subjects: 30
Study: 37289256

Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226) 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226)
Number of subjects: 25
Study: 37289263

Group type: EXPERIMENTAL
Intervention: Ankaferd hemostat
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 66
Study: 37289335

Group type: EXPERIMENTAL
Intervention: High hemoglobin target (11-13 g/dl) with darbepoetin alfa
Number of subjects: 479

Group type: COMPARATOR
Intervention: Low hemoglobin target (9-11 g/dl)
Number of subjects: 479
Study: 37289448

Group type: EXPERIMENTAL
Intervention: SB15 (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Number of subjects: 449

Group type: COMPARATOR
Intervention: AFL (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: SB15
Number of subjects: 449

Group type: COMPARATOR
Intervention: AFL
Number of subjects: 449
Study: 37289451

Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Radiosurgery (SRS) at a median dose of 15 Gy in 1 fraction or 24 Gy in 3 fractions, delivered at a median of 2 days before resection.
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 404
Study: 37289454

Group type: EXPERIMENTAL
Intervention: Peer comparison feedback (monthly emails)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no peer comparison feedback)
Number of subjects: 201
Study: 37289502

Group type: EXPERIMENTAL
Intervention: State cannabis registration (SCR) card ownership
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37289535

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Active education control (ED)
Number of subjects: 328
Study: 37289541

Group type: EXPERIMENTAL
Intervention: Flu-IVIG treatment in IBV-infected patients (n = 62)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Flu-IVIG treatment in IAV-infected patients (n = 50)
Number of subjects: 112
Study: 37289583

Group type: EXPERIMENTAL
Intervention: PrEP initiation during pregnancy
Number of subjects: 2949

Group type: EXPERIMENTAL
Intervention: PrEP persistence at 9 months postpartum
Number of subjects: 2949

Group type: EXPERIMENTAL
Intervention: Self-reported adherence to PrEP
Number of subjects: 2949

Group type: EXPERIMENTAL
Intervention: Quantifiable TFV-DP concentrations
Number of subjects: 2949

Group type: EXPERIMENTAL
Intervention: Predictors of PrEP initiation and persistence
Number of subjects: 2949
Study: 37289650

Group type: EXPERIMENTAL
Intervention: Mobile Mindfulness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37289666

Group type: EXPERIMENTAL
Intervention: WHO first line regimens (Group 1-Access)
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: WHO second-line cephalosporins (Group 2-'Low' Watch)
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Regimen providing partial extended-spectrum beta-lactamase (ESBL)/pseudomonal coverage (Group 3-'Medium' Watch)
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Carbapenem (Group 4-'High' Watch)
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Reserve antibiotic (Group 5, largely colistin-based)
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Initial regimens in Groups 1 to 4 escalated to carbapenems
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Blood culture pathogen positive
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Mortality if blood cultures were positive for pathogens
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: Baseline NeoSep Severity Score
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: NeoSep Severity Score risk groups
Number of subjects: 3204

Group type: EXPERIMENTAL
Intervention: NeoSep Recovery Score
Number of subjects: 3204
Study: 37289760

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR) training
Number of subjects: 277

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 277
Study: 37290035

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus olaparib
Number of subjects: 793

Group type: COMPARATOR
Intervention: Next-generation hormonal agent (NHA)
Number of subjects: 793

Group type: COMPARATOR
Intervention: NHA
Number of subjects: 793
Study: 37290102

Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg IV)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo (2 mL normal saline IV)
Number of subjects: 164
Study: 37290104

Group type: EXPERIMENTAL
Intervention: RRSO (Risk-Reducing Salpingo-Oophorectomy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-RRSO (Ovarian Conservation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RRSO with hormone use
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RRSO without hormone use
Number of subjects: 100
Study: 37290106

Group type: EXPERIMENTAL
Intervention: Labor induction at 39 weeks of gestation
Number of subjects: 6058
Study: 37290346

Group type: EXPERIMENTAL
Intervention: Informed Consent (IC) risk of harm statement for dry needling
Number of subjects: 5
Study: 37290461

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cabozantinib (1200 mg intravenously every 3 weeks + 60 mg orally once daily)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Cabozantinib (60 mg orally once daily)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cabozantinib
Number of subjects: 522

Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 522
Study: 37290468

Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cisplatin-fluorouracil
Number of subjects: 240
Study: 37290591

Group type: EXPERIMENTAL
Intervention: VIR-2218 (200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ALN-HBV
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VIR-2218
Number of subjects: 24
Study: 37290730

Group type: EXPERIMENTAL
Intervention: e-PROs (electronic patient-reported outcomes)
Number of subjects: 154
Study: 37290740

Group type: EXPERIMENTAL
Intervention: Total energy expenditure (TEE) assessed by 24-h whole-room indirect calorimeter
Number of subjects: 31

Group type: COMPARATOR
Intervention: Cancer-specific predicted energy requirements (25-30 kcal/kg)
Number of subjects: 31
Study: 37290822

Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (phacoemulsification and lens implantation)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 72
Study: 37290823

Group type: EXPERIMENTAL
Intervention: Tessellated fundus
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Diffuse chorioretinal atrophy
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Nasal macular ChT
Number of subjects: 579
Study: 37290915

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA PET/CT imaging
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prostate bed salvage radiotherapy (SRT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NCCN high-risk features, stage > pT3 and ISUP score > 3
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quartiles of PSA
Number of subjects: 100
Study: 37290947

Group type: EXPERIMENTAL
Intervention: Clinical decision rule (Marburg Heart Score combined with hs-cTnI-POCT, limit of detection 1.6 ng/L, cut-off value 3.8 ng/L)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 1500
Study: 37290945

Group type: EXPERIMENTAL
Intervention: Pour-flush toilet and septic tank intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control sites (original criteria)
Number of subjects: 400
Study: 37290967

Group type: EXPERIMENTAL
Intervention: Rituximab de-escalation (various regimens including discontinuations and switches to oral treatment)
Number of subjects: 137
Study: 37290996

Group type: EXPERIMENTAL
Intervention: INCB053914 (monotherapy)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: INCB053914 + cytarabine (AML)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: INCB053914 + azacitidine (AML)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: INCB053914 + ruxolitinib (MF)
Number of subjects: 97
Study: 37291118

Group type: EXPERIMENTAL
Intervention: KSHV DNA seropositivity in DCM patients
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: KSHV DNA load in plasma
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: KSHV DNA seropositivity and cardiovascular outcomes
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: KSHV DNA load in heart tissues
Number of subjects: 696
Study: 37291210

Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 37291212

Group type: EXPERIMENTAL
Intervention: AEF0117, a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1)
Number of subjects: 0
Study: 37291428

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) scoring system
Number of subjects: 43

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: pCLE diagnostic scoring
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Local regrowth detection
Number of subjects: 43
Study: 37291448

Group type: EXPERIMENTAL
Intervention: Concomitant medication that inhibits or induces CYP3A4, TSPO genetic status, age, BMI, and sex
Number of subjects: 0
Study: 37291541

Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position with positive pressure ventilation (RT/PPV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ramp position with zero end-expiratory pressure (RP/ZEEP)
Number of subjects: 50
Study: 37291543

Group type: EXPERIMENTAL
Intervention: Child in Context Intervention (CICI) - individualized, goal-oriented, home-based tele-rehabilitation intervention comprising seven tele-rehabilitation sessions, one in-person parent seminar, and four digital school meetings over a 4- to 5-month period.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Child in Context Intervention (CICI) - psychoeducation about targeted acquired brain injury-related problems.
Number of subjects: 23
Study: 37291599

Group type: EXPERIMENTAL
Intervention: tCBT + TAU
Number of subjects: 231

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 231
Study: 37291651

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg/h continuous infusion after initial loading doses of 0.5 μg/kg for 15 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 μg/kg/h continuous infusion after initial loading doses of 0.75 μg/kg for 15 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg/h continuous infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 μg/kg/h continuous infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam 0.03 mg/kg at anaesthesia induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 μg/kg
Number of subjects: 60
Study: 37291677

Group type: EXPERIMENTAL
Intervention: 200 mg IV imatinib twice daily for a maximum of seven days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 200 mg IV imatinib twice daily for a maximum of seven days in a subgroup of patients with high IL-6, TNFR1 and SP-D levels (n=20)
Number of subjects: 66
Study: 37291679

Group type: COMPARATOR
Intervention: Post-acute COVID-19 in ARD patients (≥ 4 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Post-acute COVID-19 in non-ARD controls (≥ 4 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Post-acute COVID-19 in ARD patients (> 12 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Post-acute COVID-19 in non-ARD controls (> 12 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: ≥ 3 symptoms in ARD patients (≥ 4 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: ≥ 3 symptoms in non-ARD controls (≥ 4 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: ≥ 3 symptoms in ARD patients (> 12 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: ≥ 3 symptoms in non-ARD controls (> 12 weeks)
Number of subjects: 108
Study: 37291721

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy measurements (phase angle, fat mass, fat-free mass)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phase angle improvement in the first month postoperatively
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low perioperative and 1-mo phase angles
Number of subjects: 60
Study: 37291722

Group type: EXPERIMENTAL
Intervention: CKD (Chronic Kidney Disease)
Number of subjects: 0
Study: 37291731

Group type: EXPERIMENTAL
Intervention: Low dose of propofol (1.4 mg/kg TBW)
Number of subjects: 68

Group type: COMPARATOR
Intervention: High dose of propofol (2.7 mg/kg TBW)
Number of subjects: 68
Study: 37291963

Group type: EXPERIMENTAL
Intervention: eNET intervention (10-12 sessions via videoconference)
Number of subjects: 21
Study: 37291968

Group type: EXPERIMENTAL
Intervention: Low phytic acid pea supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37292376

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) delivered by intralesional injection at 10
Number of subjects: 15
Study: 37292588

Group type: EXPERIMENTAL
Intervention: Training intervention for sustainability capacity building
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CDC-recommended funding and American Lung Association smoke-free scores (proxy for policy environment)
Number of subjects: 23
Study: 37292667

Group type: EXPERIMENTAL
Intervention: Untreated OSA symptom subtypes
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Higher baseline age
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: AHI (Apnea-Hypopnea Index)
Number of subjects: 2643
Study: 37292711

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0
Study: 37292774

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP) program
Number of subjects: 201

Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 201
Study: 37292800

Group type: EXPERIMENTAL
Intervention: Extensive protein hydrolysate formulas (EHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cow milk formula (CMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formula types
Number of subjects: 0
Study: 37292982

Group type: EXPERIMENTAL
Intervention: High-cash gift ($333 per month, or $3,996 per year)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Low-cash gift (amount not specified)
Number of subjects: 1000
Study: 37293030

Group type: EXPERIMENTAL
Intervention: d-serine + AudRem (100 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: AudRem
Number of subjects: 21
Study: 37293067

Group type: EXPERIMENTAL
Intervention: Powder-based product (potato maltodextrin) mixed with expressed breast milk, administered daily for 4 weeks
Number of subjects: 10
Study: 37293139

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (co-GDMT) as per European Society of Cardiology guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 0
Study: 37293235

Group type: EXPERIMENTAL
Intervention: Prebiotic biofilm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium alginate biofilm
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unstimulated salivary flow
Number of subjects: 10
Study: 37293434

Group type: EXPERIMENTAL
Intervention: Standardized THC/CBD 1:2 oil extract
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hemp seed oil (placebo)
Number of subjects: 24